Funded Biotechnology Startups in Raleigh
The 12 most recent funding rounds for Raleigh-based biotechnology companies range from a $100K pre-seed for AniV8 in October 2021 to Pathalys Pharma's $105…
The 12 most recent funding rounds for Raleigh-based biotechnology companies range from a $100K pre-seed for AniV8 in October 2021 to Pathalys Pharma's $105M Series B closed in August 2024, reflecting both early-stage formation activity and growth-stage capital deployment in the same market. Disclosed round sizes cluster at $2M–$6M for the majority of entries, with Sprout Pharmaceuticals ($25M convertible note, May 2022) and Inceptor Bio ($21M Series A, February 2025) representing the mid-tier.
Four of the 12 rounds carry a "Series Unknown" classification, which is common in private biotech where stage designations aren't publicly filed. The most recent activity includes Inceptor Bio's Series A in February 2025 and Opus Genetics recording a $2M round in June 2025, indicating continued deal flow into mid-2025.
Most recent rounds
12 shownRelated listings
Frequently asked
What is the largest disclosed funding round among these Raleigh biotech companies?
Pathalys Pharma raised $105M in a Series B closed on August 20, 2024 — the largest disclosed amount in this dataset. Sprout Pharmaceuticals ($25M convertible note, May 2022) and Inceptor Bio ($21M Series A, February 2025) are the next two largest by round size.
Which Raleigh biotech companies have raised funding most recently?
Opus Genetics is the most recent entry, having closed a round in June 2025 at $2M. Inceptor Bio preceded it with a $21M Series A in February 2025, making these the two most recently dated rounds in the dataset.
How does round stage break down across the 12 companies shown?
Four rounds are classified as Series Unknown, two as Series A (Gemelli Biotech at $19M and Inceptor Bio at $21M), two as Pre-Seed (AniV8 at $100K and Jellatech at $2M), and one each as Series B (Pathalys Pharma), Seed (De Novo Foodlabs), Convertible Note (Sprout Pharmaceuticals), and Venture - Series Unknown (Marius Pharmaceuticals).
What is the typical deal size for Raleigh biotech rounds in this data?
Of the 11 rounds with disclosed amounts — Dignify Therapeutics did not disclose — seven are $6M or below, with three rounds at exactly $2M (Opus Genetics, De Novo Foodlabs, Jellatech). The $105M Pathalys Pharma Series B is a clear outlier; without it, the largest single round is Sprout Pharmaceuticals at $25M.
Is there active early-stage deal flow in the Raleigh biotech market?
Three rounds in the dataset are early-stage: AniV8's $100K pre-seed (October 2021), Jellatech's $2M pre-seed (April 2021), and De Novo Foodlabs' $2M seed round (August 2024). De Novo Foodlabs represents the most recent early-stage entry, with its seed close in mid-2024.
What time span does this Raleigh biotech funding activity cover?
The 12 rounds span from April 2021 (Jellatech's pre-seed) through June 2025 (Opus Genetics). Activity is distributed across the full period: three rounds in 2021, two each in 2022 and 2023, three in 2024, and two in 2025.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.